Home
HelpTest Code CSPMM Plasma Cell Myeloma Pre-Analysis Cell Sorting, Bone Marrow
Specimen Required
Only orderable as a reflex. For more information see NGPCM / MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies.
Specimen Type: Bone marrow aspirate
Container/Tube: Lavender or pink top (EDTA) or yellow top (ACD)
Specimen Volume: 2 mL
Collection Instructions:
1. Minimum plasma cell percentage is 5%.
2. Invert several times to mix bone marrow.
3. Send bone marrow specimen in original tube. Do not aliquot.
4. Label specimen as bone marrow.
5. Fresh specimen is required for this test, as testing is performed on sorted cells.
Specimen Stability Information: Ambient (preferred) 4 days/Refrigerate
Secondary ID
618626Useful For
Pre-analysis cell sorting for the MayoComplete Plasma Cell Myeloma panel
Method Name
Only orderable as a reflex. For more information see NGPCM / MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies.
Flow Cytometric Cell Selection
Reporting Name
NGPCM Pre-Analysis Cell Sorting, BMSpecimen Type
Bone MarrowSpecimen Minimum Volume
2 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Bone Marrow | Ambient | 4 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
| Fully clotted | Reject |
| Bone marrow biopsies Slides Paraffin shavings Frozen tissues Paraffin-embedded tissues Paraffin-embedded bone marrow aspirates Extracted DNA |
Reject |
Clinical Information
Testing allows for further risk categorization of multiple myeloma (MM) through identifying additional abnormalities of prognostic and, potentially, therapeutic value. Application of targeted next-generation sequencing-based analysis is a useful adjunct to the standard evaluation of MM patients at diagnosis and relapse.
Reference Values
Only orderable as a reflex. For more information see NGPCM / MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies.
Not applicable
Interpretation
Correlation with clinical, histopathologic, and additional laboratory findings is required for final interpretation of these results. The final interpretation of results for clinical management of the patient is the responsibility of the managing physician.
Method Description
Selection of plasma cells using fluorescence-activated cell sorting is the most direct and robust method of obtaining relatively pure plasma cell populations for molecular assessment. This, in turn, augments the ability to identify key mutations and subclonal variants of possible clinical value without dilution effects from non-tumor cell DNA.(Instruction manual: BD FACSMelody Cell Sorter User's Guide. Revision 3. BD Biosciences; 03/2020)
Day(s) Performed
Monday through Saturday
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88184-Flow Cytometry; first cell surface, cytoplasmic or nuclear marker
88185 x 5-Flow Cytometry, additional cell surface, cytoplasmic or nuclear marker (each)
LOINC Code Information
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 618627 | NGPCM Pre-Analysis Cell Sort | No LOINC Needed |
| 618630 | Final Diagnosis | 22637-3 |